Elapegademase

{{Infobox drug

| drug_name =

| INN =

| type =

| image =

| caption =

| pronounce =

| tradename = Revcovi

| Drugs.com = {{drugs.com|monograph|elapegademase-lvlr}}

| DailyMedID = Elapegademase

| pregnancy_AU =

| pregnancy_category=

| routes_of_administration = Intramuscular

| class =

| ATCvet =

| ATC_prefix = L03

| ATC_suffix = AX21

| legal_CA =

| legal_CA_comment =

| legal_US = Rx-only

| legal_status =

| bioavailability =

| protein_bound =

| metabolism =

| excretion =

| CAS_number = 1709806-75-6

| PubChem =

| DrugBank = DB14712

| ChemSpiderID =

| UNII = 9R3D3Y0UHS

| KEGG = D11017

| ChEBI =

| ChEMBL =

| StdInChI =

| StdInChIKey =

| synonyms = elapegademase-lvlr

| chemical_formula =

| molecular_weight =

| SMILES =

| IUPAC_name =

}}

Elapegademase, sold under the brand name Revcovi, is a medication for the treatment of the rare disease adenosine deaminase deficiency-SCID in children and adults.{{cite book | vauthors = Skidmore-Roth L |title=Mosby's 2023 Nursing Drug Reference |date=2022 |publisher=Elsevier Health Sciences |isbn=978-0-323-93330-8 |page=429 | chapter = Elapegademase | chapter-url=https://books.google.com/books?id=S2ZsEAAAQBAJ&dq=Elapegademase&pg=PA429}}

It is a recombinant enzyme{{cite web |title=Elapegademase: Drug Information |url=https://www.uptodate.com/contents/elapegademase-drug-information|url-access=subscription |website=www.uptodate.com |accessdate=28 March 2019}} that is administered weekly by intramuscular injection.{{cite web |title=LexiComp: Elapegademase-lvlr |url=http://online.lexi.com/lco/action/doc/retrieve/docid/fc_atoz2/6712838?hl=832641|url-access=subscription |website=LexiComp |accessdate=28 March 2019}}

Elapegademase may interact with PEGylated drugs.

Elapegademase-lvlr was approved by the U.S. Food and Drug Administration (FDA) in 2018.{{cite web | title=Drug Approval Package: Revcovi | website=U.S. Food and Drug Administration (FDA) | date=7 November 2018 | url=https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/761092Orig1s000TOC.cfm | archive-url=https://web.archive.org/web/20191226221713/https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/761092Orig1s000TOC.cfm | url-status=dead | archive-date=December 26, 2019 | access-date=26 December 2019}}{{cite web | title=Elapegademase-lvlr Orphan Drug Designation and Approval | website=U.S. Food and Drug Administration (FDA) | date=24 December 1999 | url=https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=467514 | access-date=26 December 2019}}{{cite web | title=Drug Trial Snapshot: Revcovi | website=U.S. Food and Drug Administration (FDA) | date=5 October 2018 | url=https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trial-snapshot-revcovi | access-date=26 December 2019}} Leadiant Biosciences was awarded a priority review voucher for its development under the pediatric rare diseases program.{{cite web |title=Elapegademase - Leadiant Biosciences | work = AdisInsight |url=https://adisinsight.springer.com/drugs/800034312 |url-access=subscription|publisher = Springer Nature Switzerland AG |accessdate=28 March 2019}}